Page 2
Exscientia expands IPO to over $350m
The cancer drug developer has closed its initial public offering after underwriters exercised the greenshoe option.
Pyxis picks price range
UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.
Exscientia establishes Nasdaq listing
The Dundee spinout has raised more than $304m in its IPO in the US, with another $160m secured through a concurrent private placement.
Li-S Energy celebrates market debut
Based on research at Deakin University, Li-S Energy has gone public on the Australian Stock Exchange after raising $25m in its initial public offering.
Lucid Diagnostics lines up IPO
Case Western Reserve University-linked Lucid Diagnostics is seeking an initial public offering that would net it up to $57.5m.
Oxford Nanopore sets IPO plans in motion
Oracle has signed up to be a cornerstone investor for Oxford Nanopore’s initial public offering, putting up half of the $410m target.
Prenetics tests out $1.25bn reverse merger
Genetic testing services provider Prenetics, a spinout of City University of Hong Kong, will hold a reverse merger at a $1.25bn valuation.
Context Therapeutics frames IPO plans
Based on research at Drexel University, Context Therapeutics is seeking to raise up to $21m in an initial public offering on Nasdaq.
Exscientia explores Nasdaq IPO
Dundee spinout Exscientia is continuing a busy fundraising year with a filing for an IPO in the US and a $35m concurrent private placement.